We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

the group's global head of respiratory and immunology R&D. Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, eosinophilic ...

GSK plc (NYSE:GSK) specializes in pharmaceuticals, vaccines, and consumer health products, with a strong focus on immunology. Its specialty medicines division targets complex diseases like lupus ...

GSK respiratory, immunology/inflammation R&D global head and SVP Kaivan Khavandi said: “Today’s data build on the body of evidence supporting depemokimab as an ultra-long-acting treatment and ...

Relation has announced two strategic collaborations with GSK, focusing on the discovery and validation of therapeutics that target fibrotic diseases and osteoarthritis. Relation will obtain a $45m ...

GSK looks like it is starting to show the benefit of a revamp of its business under chief executive Emma Walmsley, with recent product launches driving a 10% rise in sales in the first quarter of ...

Sales are rising in all areas, HIV, Immunology/Respiratory as well as ... filings are expected in 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best immunology stocks to buy now.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other best immunology stocks to buy now.